Latest Stories

N
Earnings Call

NEOG Q4 Deep Dive: Operational Improvements and New Leadership Drive Upbeat Outlook

Life sciences company Neogen (NASDAQ:NEOG) reported Q4 CY2025 results topping the market’s revenue expectations, but sales fell by 2.8% year on year to $224.7 million. The company’s full-year revenue guidance of $850 million at the midpoint came in 2.8% above analysts’ estimates. Its non-GAAP profit of $0.10 per share was 50% above analysts’ consensus estimates.

Jan 09, 2026
T
Screener

1 Services Stock to Target This Week and 2 We Turn Down

Business services providers play a critical role for enterprises, assisting them with everything from new hardware integrations to consulting and marketing. But increasing competition from AI-driven upstarts has tempered enthusiasm, limiting the industry’s gains to 5.4% over the past six months. This return lagged the S&P 500’s 10.5% climb.

Jan 09, 2026
W
Screener

1 Large-Cap Stock to Keep an Eye On and 2 We Turn Down

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

Jan 09, 2026
M
Screener

1 Unpopular Stock That Deserves Some Love and 2 That Underwhelm

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

Jan 09, 2026
M
Screener

1 Profitable Stock with Exciting Potential and 2 Facing Challenges

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Jan 09, 2026
P
Screener

1 Insurance Stock to Own for Decades and 2 We Brush Off

Insurance companies serve as the backbone of risk management, providing essential protection and financial security for individuals and businesses. But concerns about claims severity and tightening regulations have tempered enthusiasm, limiting the industry’s gains to 5.4% over the past six months. This return lagged the S&P 500’s 10.5% climb.

Jan 09, 2026
A
Screener

1 Mooning Stock to Keep an Eye On and 2 Facing Challenges

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

Jan 09, 2026
P
Screener

1 Profitable Stock Worth Investigating and 2 We Avoid

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Jan 09, 2026
N
Screener

3 Market-Beating Stocks for Long-Term Investors

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

Jan 09, 2026
T
Screener

3 Profitable Stocks That Concern Us

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Jan 09, 2026